Drug Profile
SERCA 2a gene therapy - Theragene Pharmaceuticals
Alternative Names: AAV1/SERCA2a; AAV1/SSERCA2a; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy; SRD-001Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Celladon; Targeted Genetics
- Developer Eiger BioPharmaceuticals, Inc.; Sardocor; Theragene Pharmaceuticals
- Class Gene therapies; Heart failure therapies
- Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Heart failure
- No development reported Pulmonary arterial hypertension; Renal failure
- Discontinued Urinary incontinence
Most Recent Events
- 01 Feb 2024 Sardocor plans a phase MUSIC-DMD I trial for Dilated cardiomyopathy in March 2024 (Intracoronary, Infusion) (NCT06224660)
- 24 Aug 2023 Phase-I clinical trials in Heart failure (In adults, In the elderly) in USA (Intracoronary) (NCT06061549)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)